We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Senate Panel Gives Blessing to FDA Appropriations Bill

Senate Panel Gives Blessing to FDA Appropriations Bill

July 17, 2015

The Senate Appropriations Committee has voted 28-2 to pass a bill that would grant the FDA $4.6 billion in total funding, an increase of $116 million over FY 2015.

Among the provisions is $134.5 million in medical device user fees, the same as provided for in the House version. It also provides for $424.6 million in appropriations — slightly more than what is included in the House version.

The $148.3 billion measure provides the agency with $2.6 billion in discretionary funds, $107 million less than what was sought in the President Barack Obama’s budget request. The funding numbers are in line with what the House Appropriations Committee agreed to July 8.

The bill also includes a $3 million increase to combat antibiotic resistance — $12 million less than the budget request — as well as a $2 million increase for the Precision Medicine Initiative, which was $8 million less than requested.

The White House introduced the PMI initiative earlier this year with the intent of accelerating biomedical discoveries. The initiative is designed to approach disease treatment and prevention by taking individual variability in genes, environment and lifestyle of each person into account.

While praising the committee’s work and voting in favor of the measure, Sen. Barbara Mikulski (D-Md.), the top Democrat on the committee, said “the bill did fall short.”

She highlighted the efforts of Sens. Jerry Moran (R-Kan.) and Jeff Merkley (D-Ore.), saying in a prepared statement that they “have done a good job with the spartan, sequester-based allocation. But the bill is $1.1 billion short of the president’s request and $65 million below the fiscal year 2015 funding level.”

In her statement, Mikulski stressed that the FDA needs more funding to remain “the gold standard for drug, medical device and food safety.” Merkley agreed, and while he praised the committee’s work, noting that “tough choices were necessary,” he said more needed to be done.

He offered an amendment that, among other things, would have boosted FDA funding by $103 million. His amendment also included $12 million to combat antibiotic resistance and $8 million for the PMI. It failed in 14-16 in a vote that followed party lines.

The bill will now go on to the full Senate for consideration. The House version, H.R. 3049, was introduced in that chamber July 14. The bill, S. 1800, is available at www.fdanews.com/072015-senate-appropriations.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing